Cancer Trial Data for FOG-001 to be Presented by Parabilis at ASCO GI Cancers Symposium Parabilis Medicines, formerly known as Fog Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing transformative treatments for cancer patients, today announced that it will present…
Clinical Data Registry: McKesson’s Practice Insights Named 2025 QCDR by CMS For the ninth year in a row, McKesson has been named a Qualified Clinical Data Registry (QCDR) by the Centers for Medicare & Medicaid Services (CMS), securing approval to…
Verastem Oncology Unveils Bold 2025 Priorities for RAS/MAPK Pathway Cancer Pipeline Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new treatments for RAS/MAPK pathway-driven cancers, has outlined its strategic priorities for 2025, as well as the key milestones…
Congress Spotlight: Merz Aesthetics® Unveils Ultherapy PRIME® at 2025 IMCAS Merz Aesthetics is launching Ultherapy PRIME® across Europe, the Middle East, and Africa, marking an exciting evolution of the non-invasive Ultherapy® skin lifting technology. This advanced version of Ultherapy® promises…
Viruses Neutralized by Electromagnetic Waves: e4life at Arab Health Dubai e4life will play a key role at the landmark 50th edition of Arab Health, the premier health trade fair in the Middle East. The Italian company will showcase its cutting-edge…
Innovation by USound Enables Advanced Health Monitoring in TWS Earphones USound, a global leader in Micro Electronic Mechanical Systems (MEMS) speakers, has unveiled a groundbreaking innovation that will enable true wireless systems (TWS) earphones to feature advanced health monitoring capabilities…
Diabetes Breakthrough: IPA Pioneers AI-Designed GLP-1 Therapies ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has pioneered a new class of GLP-1 therapies developed entirely through artificial intelligence, aiming to enhance the efficacy, safety, longevity, and patient satisfaction in diabetes treatment. These…
Vaccines Development: Vaxxas and CEPI Advance $4.8M Program for Needle-Free mRNA Vaxxas, a clinical-stage biotechnology company focused on commercializing its innovative high-density microarray patch (HD-MAP) vaccination platform, today announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has approved the…
Collaboration Announced Between Simulations Plus and ETC for GastroPlus® Simulations Plus, Inc. (Nasdaq: SLP), a leader in biosimulation and performance solutions for the biopharma industry, has entered into an exciting new collaboration with the Enabling Technologies Consortium (ETC). This funded…
Pancreatic Cancer Subtypes Unveiled by BPGbio at ASCO GI 2025 for Tailored Treatment BPGbio, Inc., a clinical-stage biopharma company specializing in mitochondrial biology and protein homeostasis, today revealed new findings in pancreatic cancer subtyping from its long-term Project Survival® (NCT2781012)…
DNA Nanobots Appoints Dr. John C. Byrd to Scientific Advisory Board DNA Nanobots, a leader in biotechnology specializing in DNA nanoparticles for targeted therapeutics, has announced the addition of Dr. John C. Byrd, M.D., to its Scientific Advisory Board (SAB).…
Partners at Red Cell Welcome Timothy G. Ferris, MD, to Lead Healthcare Practice Red Cell Partners, a firm dedicated to incubating and investing in technology-driven companies that are revolutionizing healthcare, cyber, and national security, has announced that Dr. Timothy G.…
